The Clinical Analysis On The Expression Of CD7 In Acute Myeloid Leukemia(non-M3)

Objective:To observe the expression level of CD7 in(acute myeloid leukemia,AML)of non-M3 acute myeloid leukemia,to analyze the correlation between the expression of CD7 antigen and the clinical features and efficacy of AML,and to evaluate its prognostic significance.Methods:The clinical data of 259 patients with newly diagnosed AML(non-M3 type)treated in the hematology department of Shengjing Hospital affiliated to China Medical University from January 2013 to September 2019 were collected and selected.according to whether the expression rate of CD7 in immunophenotype was≥20%,the patients were divided into two groups:CD7 positive group and CD7 negative group.The clinical and laboratory data of the two groups were retrospectively analyzed and compared,and the results of complete remission rate(Complete Remission,CR)and minimal residual disease(minimal residual disease,MRD)after the first chemotherapy were compared.The survival status of the patients was followed up,and the recurrence rate,progression-free survival time(progression-free survival,PFS)and total survival time(overall survival,OS)were observed.SPSS25.0 is used for statistical analysis of the data.Results:The expression rate of CD7 in undifferentiated acute myeloid leukemia(M1)was significantly higher than that in other leukemia subtypes(P<0.05).The expression rate of CD7 in undifferentiated acute myeloid leukemia(M1)was significantly higher than that in other leukemia subtypes(P<0.05).The expression rate of CD7 in undifferentiated acute myeloid leukemia(M1)was significantly higher than that in other leukemia subtypes(P<0.05).The median age in patients with CD7+[49(34 minutes 60)]was significantly lower than that in patients with CD7-[53(41 minutes 64)],the count of newly diagnosed White blood cell(white blood cell,WBC)was 21.60(66.00)×10~9/L,and the proportion of primordial cells in peripheral blood was 62.5(27.3)(81.0)%,significantly higher than that in patients with CD7~-.Most of the patients with CD7~+AML occurred in middle and high risk karyotypes,which was significantly different from that in CD7~-group(P<0.05).There was no significant difference in the incidence of adverse gene mutations between CD7~+AML patients and CD7~-patients.In patients with FLT3-ITD gene mutations,OS in CD7~+patients was significantly lower than that in CD7~-patients.The MRD of CD7~+AML patients after chemotherapy was significantly lower than that of CD7~-patients,but there was no significant difference in CR rate,recurrence rate,3-year relapse-free survival rate and 5-year overall survival rate between CD7~+patients and CD7~-patients after the first chemotherapy.Conclusion:1.CD7 was highly expressed in M1 subtype,and most of the CD7~+AML karyotypes were cytogenetic risk stratification with moderate prognosis and poor prognosis.2.The OS of CD7~+AML patients with FLT3-ITD gene mutation was significantly lower than that of CD7~-patients.3.There was no significant difference in the incidence of adverse gene mutation,CR rate,recurrence rate,3-year relapse-free survival rate and 5-year overall survival rate between CD7~+and CD7~-AML groups.To sum up,CD7 is associated with some high risk factors of AML.The cytogenetic risk stratification of AML patients with CD7 expression is poor.The co-existence of FLT3-ITD gene mutation and CD7 antigen may lead to poor prognosis in AML patients,but CD7 can not be used as an independent prognostic factor of AML.